Cleveland BioLabs (NASDAQ: CBLI) is one of 202 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare Cleveland BioLabs to similar businesses based on the strength of its valuation, profitability, earnings, dividends, risk, analyst recommendations and institutional ownership.
Risk & Volatility
Cleveland BioLabs has a beta of -0.24, indicating that its stock price is 124% less volatile than the S&P 500. Comparatively, Cleveland BioLabs’ rivals have a beta of 1.47, indicating that their average stock price is 47% more volatile than the S&P 500.
Institutional and Insider Ownership
4.6% of Cleveland BioLabs shares are held by institutional investors. Comparatively, 48.8% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 2.4% of Cleveland BioLabs shares are held by company insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Cleveland BioLabs and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Cleveland BioLabs||$3.52 million||-$2.65 million||-4.14|
|Cleveland BioLabs Competitors||$231.40 million||-$38.89 million||-70.15|
Cleveland BioLabs’ rivals have higher revenue, but lower earnings than Cleveland BioLabs. Cleveland BioLabs is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a summary of current ratings for Cleveland BioLabs and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cleveland BioLabs Competitors||519||2474||6654||125||2.65|
As a group, “Biotechnology & Medical Research” companies have a potential upside of 18.09%. Given Cleveland BioLabs’ rivals higher probable upside, analysts plainly believe Cleveland BioLabs has less favorable growth aspects than its rivals.
This table compares Cleveland BioLabs and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cleveland BioLabs Competitors||-4,124.44%||-122.46%||-44.30%|
Cleveland BioLabs rivals beat Cleveland BioLabs on 6 of the 9 factors compared.
Cleveland BioLabs Company Profile
Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.
Receive News & Ratings for Cleveland BioLabs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs Inc. and related companies with MarketBeat.com's FREE daily email newsletter.